Literature DB >> 11162238

Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.

C Van den Haute1, K Spittaels, J Van Dorpe, R Lasrado, K Vandezande, I Laenen, H Geerts, F Van Leuven.   

Abstract

The potential contribution of cyclin-dependent protein kinase 5 (cdk5) to hyperphosphorylate protein tau, as claimed in Alzheimer's disease, was investigated in vivo. We generated single, double, and triple transgenic mice that coexpress human cdk5 and its activator p35 as well as human protein tau in cerebral neurons. Whereas expression and increased cdk5-kinase activity was obtained, as measured in vitro and demonstrated in vivo, neither murine nor human protein tau was appreciably phosphorylated in the brain of double and triple transgenic mice. These mice behaved and reproduced normally. Silver impregnation and immunohistochemistry of brain sections demonstrated that neurofilament proteins became redistributed in apical dendrites of cortical neurons. This suggested a cytoskeletal effect, but no other relevant brain pathology became apparent. These observations indicate that cdk5/p35 is not a major protein tau kinase and that cdk5/p35 did not cause neurodegeneration in mouse brain, as opposed to cdk5/p25. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162238     DOI: 10.1006/nbdi.2000.0333

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  15 in total

1.  Special Issue on "Cdk5 and Brain Disorders": Prologue.

Authors:  Jyotshnabala Kanungo
Journal:  Brain Disord Ther       Date:  2012-05-31

2.  Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.

Authors:  Holger Patzke; Upendra Maddineni; Ramses Ayala; Maria Morabito; Janet Volker; Pieter Dikkes; Michael K Ahlijanian; Li-Huei Tsai
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

3.  Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.

Authors:  Jinsoo Seo; Oleg Kritskiy; L Ashley Watson; Scarlett J Barker; Dilip Dey; Waseem K Raja; Yuan-Ta Lin; Tak Ko; Sukhee Cho; Jay Penney; M Catarina Silva; Steven D Sheridan; Diane Lucente; James F Gusella; Bradford C Dickerson; Stephen J Haggarty; Li-Huei Tsai
Journal:  J Neurosci       Date:  2017-09-14       Impact factor: 6.167

4.  Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice.

Authors:  Diego Piedrahita; Israel Hernández; Alejandro López-Tobón; Dmitry Fedorov; Boguslaw Obara; B S Manjunath; Ryan L Boudreau; Beverly Davidson; Frank Laferla; Juan Carlos Gallego-Gómez; Kenneth S Kosik; Gloria Patricia Cardona-Gómez
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

5.  Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.

Authors:  David Muyllaert; Dick Terwel; Anna Kremer; Kristina Sennvik; Peter Borghgraef; Herman Devijver; Ilse Dewachter; Fred Van Leuven
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

6.  Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease.

Authors:  Tomasz Jaworski; Sebastian Kügler; Fred Van Leuven
Journal:  Int J Alzheimers Dis       Date:  2010-08-24

Review 7.  Contribution of hypoxia to Alzheimer's disease: is HIF-1alpha a mediator of neurodegeneration?

Authors:  O O Ogunshola; X Antoniou
Journal:  Cell Mol Life Sci       Date:  2009-09-11       Impact factor: 9.261

8.  Targeting Cdk5 activity in neuronal degeneration and regeneration.

Authors:  Jyotshnabala Kanungo; Ya-li Zheng; Niranjana D Amin; Harish C Pant
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

Review 9.  Cdk5 as a drug target for the treatment of Alzheimer's disease.

Authors:  Lit-Fui Lau; Patricia A Seymour; Mark A Sanner; Joel B Schachter
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

10.  A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons.

Authors:  Gerardo Morfini; Györgyi Szebenyi; Hannah Brown; Harish C Pant; Gustavo Pigino; Scott DeBoer; Uwe Beffert; Scott T Brady
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.